Astragaloside IV Protects Against Podocyte Apoptosis by Inhibiting Oxidative Stress Via Activating PPARγ-Klotho-FoxO1 Axis in Diabetic Nephropathy
Overview
Biology
Physiology
Authors
Affiliations
Aims: Podocyte apoptosis plays an important role in the pathogenesis of diabetic nephropathy (DN). Astragaloside IV (AS-IV) has been shown to protect against podocyte apoptosis. Here we aim to investigate the mechanism responsible for the protective effects of AS-IV.
Main Methods: Diabetic db/db mice and high glucose (HG)-cultured podocytes were treated with AS-IV. Renal function and histopathological changes were measured to evaluate the therapeutic effects of AS-IV against DN. Adenovirus-mediated Klotho overexpression, Klotho siRNA, and PPARγ inhibitor were applied in vitro to investigate the potential mechanism. The expression levels of mRNA and proteins were analyzed by qRT-PCR, western blot or immunofluorescence. Intracellular ROS and mitochondrial superoxide were detected by DHE and MitoSOx Red, respectively. Cell apoptosis was evaluated by TUNEL staining and flow cytometry.
Key Findings: AS-IV improved renal function and ameliorated podocyte injury in db/db mice accompanied with enhanced Klotho expression in glomerular podocytes. In vitro, AS-IV inhibited HG-induced podocyte apoptosis and restored HG-inhibited Klotho expression, whereas Klotho knockdown abrogated the anti-apoptosis action of AS-IV. Further study showed that adenovirus-mediated Klotho overexpression enhanced Forkhead transcription factor O1 (FoxO1)-dependent antioxidant activity and attenuated HG-evoked oxidative stress and apoptosis. AS-IV prevented HG-induced FoxO1 inhibition and oxidative stress, whereas Klotho knockdown reversed these effects. Cotreatment with PPARγ inhibitor T0070907 abolished AS-IV-induced Klotho expression and anti-apoptosis action.
Significance: These data suggested that AS-IV attenuated podocyte apoptosis presumably by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 signaling pathway, thereby ameliorating DN. This study provided new insights into the molecular mechanisms of AS-IV against DN.
Teh Y, Mualif S, Izzati Mohd Noh N, Lim S Int J Mol Sci. 2025; 26(1.
PMID: 39795863 PMC: 11719669. DOI: 10.3390/ijms26010003.
Huang F, Huang S, Sun K, Chen Y, Xie G, Bao J Sci Rep. 2025; 15(1):435.
PMID: 39748100 PMC: 11696807. DOI: 10.1038/s41598-024-84704-6.
Liu F, Yang Z, Li J, Wu T, Li X, Zhao L Mol Med. 2024; 30(1):265.
PMID: 39707216 PMC: 11660506. DOI: 10.1186/s10020-024-01020-5.
Exploring potential targets for natural product therapy of DN: the role of SUMOylation.
Wang J, Zhang R, Wu C, Wang L, Liu P, Li P Front Pharmacol. 2024; 15:1432724.
PMID: 39431155 PMC: 11486755. DOI: 10.3389/fphar.2024.1432724.
Xue H, Chen Y, Wang S, Yang Y, Cai L, Zhao J J Diabetes Res. 2024; 2024:5216113.
PMID: 39308629 PMC: 11416176. DOI: 10.1155/2024/5216113.